Close this search box.

Sensus Healthcare to Host Third Quarter 2017 Financial Results and Business Update Conference Call on November 2, 2017

October 25, 2017

BOCA RATON, Fla., Oct. 25, 2017 Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radio Therapy (SRT), announces that management will hold a conference call on Thursday, November 2, 2017 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

To access the conference call, the dial-in numbers are (844) 666-7589 (U.S. Toll Free), and (443) 961-0433 (International). All listeners should provide the operator with the following conference ID: 1678917.

Following the conclusion of the conference call, a replay will be available through November 8, 2017 and can be accessed by dialing (855) 859-2056 (U.S. Toll Free), (404) 537-3406 (International). All listeners should provide the operator with the following conference ID: 1678917. The call will also be archived on the Company’s website for a period of time at

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
[email protected]

View original content:

SOURCE Sensus Healthcare